BRIEF-Simcere Pharmaceutical Says Option To License Agreement Of Sim0500 With Abbvie

Reuters

2025/01/13

Jan 13 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK:

OPTION TO LICENSE AGREEMENT OF SIM0500 WITH ABBVIE FOR RIGHTS OUTSIDE GREATER CHINA
OPTION TO LICENSE AGREEMENT OF SIM0500 WITH ABBVIE FOR RIGHTS OUTSIDE GREATER CHINA
UNDER DEAL CO TO RECEIVE UPFRONT PAYMENT FROM ABBVIE, ELIGIBLE TO RECEIVE OPTION FEES & MILESTONE PAYMENTS OF UP TO $1.055 BILLION

Further company coverage: 2096.HK

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2503586364"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503586364\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503586364?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-13 23:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503586364","market":"us","top_or_hot":-1,"title":"BRIEF-Simcere Pharmaceutical Says Option To License Agreement Of Sim0500 With Abbvie","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Simcere Pharmaceutical Says Option To License Agreement Of Sim0500 With Abbvie </title></head><body><p><span>Jan 13 (Reuters)</span><span> - </span>Simcere Pharmaceutical Group Ltd <span>2096.HK</span>:</p><ul><li><p>OPTION TO LICENSE AGREEMENT OF SIM0500 WITH ABBVIE FOR RIGHTS OUTSIDE GREATER CHINA</p></li><li><p>OPTION TO LICENSE AGREEMENT OF SIM0500 WITH ABBVIE FOR RIGHTS OUTSIDE GREATER CHINA</p></li><li><p>UNDER DEAL CO TO RECEIVE UPFRONT PAYMENT FROM ABBVIE, ELIGIBLE TO RECEIVE OPTION FEES &amp; MILESTONE PAYMENTS OF UP TO $1.055 BILLION</p></li></ul><p>Further company coverage: <span>2096.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Simcere Pharmaceutical Says Option To License Agreement Of Sim0500 With Abbvie</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Simcere Pharmaceutical Says Option To License Agreement Of Sim0500 With Abbvie\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-01-13 23:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Simcere Pharmaceutical Says Option To License Agreement Of Sim0500 With Abbvie </title></head><body><p><span>Jan 13 (Reuters)</span><span> - </span>Simcere Pharmaceutical Group Ltd <span>2096.HK</span>:</p><ul><li><p>OPTION TO LICENSE AGREEMENT OF SIM0500 WITH ABBVIE FOR RIGHTS OUTSIDE GREATER CHINA</p></li><li><p>OPTION TO LICENSE AGREEMENT OF SIM0500 WITH ABBVIE FOR RIGHTS OUTSIDE GREATER CHINA</p></li><li><p>UNDER DEAL CO TO RECEIVE UPFRONT PAYMENT FROM ABBVIE, ELIGIBLE TO RECEIVE OPTION FEES &amp; MILESTONE PAYMENTS OF UP TO $1.055 BILLION</p></li></ul><p>Further company coverage: <span>2096.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1989772840.SGD","symbol_name":"CPR Invest - Climate Action A2 Acc SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O913Z:1","article_id":"2503586364","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503586364","pubTimestamp":1736780844,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Simcere Pharmaceutical Says Option To License Agreement Of Sim0500 With Abbvie Jan 13  - Simcere Pharmaceutical Group Ltd 2096.HK:OPTION TO LICENSE AGREEMENT OF SIM0500 WITH ABBVIE FOR RIGHTS OUTSIDE GREATER CHINAOPTION TO LICENSE AGREEMENT OF SIM0500 WITH ABBVIE FOR RIGHTS OUTSIDE GREATER CHINAUNDER DEAL CO TO RECEIVE UPFRONT PAYMENT FROM ABBVIE, ELIGIBLE TO RECEIVE OPTION FEES & MILESTONE PAYMENTS OF UP TO $1.055 BILLIONFurther company coverage: 2096.HK ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","BK4581":"高盛持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","ABBV":"艾伯维公司","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","02096":"先声药业","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","BK4550":"红杉资本持仓","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC"},"translate_title":"简介-先声药业表示可选择与艾伯维签订Sim0500许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9,"02096":0.9},"content_text":"BRIEF-Simcere Pharmaceutical Says Option To License Agreement Of Sim0500 With Abbvie Jan 13 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK:OPTION TO LICENSE AGREEMENT OF SIM0500 WITH ABBVIE FOR RIGHTS OUTSIDE GREATER CHINAOPTION TO LICENSE AGREEMENT OF SIM0500 WITH ABBVIE FOR RIGHTS OUTSIDE GREATER CHINAUNDER DEAL CO TO RECEIVE UPFRONT PAYMENT FROM ABBVIE, ELIGIBLE TO RECEIVE OPTION FEES & MILESTONE PAYMENTS OF UP TO $1.055 BILLIONFurther company coverage: 2096.HK ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}